Details for New Drug Application (NDA): 216774
✉ Email this page to a colleague
The generic ingredient in ALVAIZ is eltrombopag choline. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the eltrombopag choline profile page.
Summary for 216774
Tradename: | ALVAIZ |
Applicant: | Teva Pharms Inc |
Ingredient: | eltrombopag choline |
Patents: | 0 |
Pharmacology for NDA: 216774
Suppliers and Packaging for NDA: 216774
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774 | NDA | Teva Pharmaceuticals, Inc. | 0480-3273 | 0480-3273-56 | 30 TABLET, FILM COATED in 1 BOTTLE (0480-3273-56) |
ALVAIZ | eltrombopag choline | TABLET;ORAL | 216774 | NDA | Teva Pharmaceuticals, Inc. | 0480-3274 | 0480-3274-56 | 30 TABLET, FILM COATED in 1 BOTTLE (0480-3274-56) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 9MG BASE | ||||
Approval Date: | Nov 29, 2023 | TE: | RLD: | Yes |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 18MG BASE | ||||
Approval Date: | Nov 29, 2023 | TE: | RLD: | Yes |
Profile for product number 003
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 36MG BASE | ||||
Approval Date: | Nov 29, 2023 | TE: | RLD: | Yes |
Complete Access Available with Subscription